Myraqa
Strengthening its Regulatory Strategy Support, Illumina Buys Myraqa
NEW YORK (GenomeWeb) – Illumina today announced it has acquired regulatory and quality consulting firm Myraqa for an undisclosed amount.
Big Names Join Clinical Proteomics Push in 2011, Offering Ray of Optimism Amidst Difficult Year
Premium
By Adam Bonislawski
Proteomics in 2011 continued its long, hard slog toward the clinic, battling now-familiar challenges like sluggish test sales, unproven platforms, and the vagaries of the regulatory process.
The plan, which the agency made public on Jan. 19, detailed a number of draft guidances FDA intends to put out this year; but it's the items that it declined to address, like the development of a new Class IIb device category, that could be the most significant.